Ultragenyx Pharmaceutical Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RARE$16.41+6.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenues:
Product sales	$77,251	$42,349	$213,545	$128,757
Royalty revenue	62,243	55,703	181,808	106,916
Collaboration and license	—	—	—	71,184
Total revenues	139,494	98,052	395,353	306,857
Operating expenses:
Cost of sales	21,021	10,987	59,834	33,158
Research and development	170,109	157,245	510,099	487,892
Selling, general and administrative	80,351	74,917	239,115	232,966
Total operating expenses	271,481	243,149	809,048	754,016
Loss from operations	(131,987)	(145,097)	(413,695)	(447,159)
Interest income	10,731	5,881	26,956	18,135
Change in fair value of equity investments	678	(1,419)	433	(1,492)
Non-cash interest expense on liabilities for sales of future royalties	(15,712)	(17,665)	(47,519)	(48,676)
Other income (expense)	3,077	(699)	(357)	(2,380)
Loss before income taxes	(133,213)	(158,999)	(434,182)	(481,572)
Provision for income taxes	(303)	(650)	(1,616)	(1,877)
Net loss	$(133,516)	$(159,649)	$(435,798)	$(483,449)
Net loss per share, basic and diluted	$(1.40)	$(2.23)	$(4.91)	$(6.81)
Shares used in computing net loss per share, basic and diluted	95,493,996	71,664,493	88,811,157	70,987,801

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.